Profile data is unavailable for this security.
About the company
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
- Revenue in CHF (TTM)1.27bn
- Net income in CHF112.06m
- Incorporated1904
- Employees3.93k
- LocationSiegfried Holding AGUntere Bruehlstrasse 4ZOFINGEN 4800SwitzerlandCHE
- Phone+41 627461111
- Fax+41 627461102
- Websitehttps://www.siegfried.ch/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polypeptide Group AG | 321.25m | -50.87m | 1.09bn | 1.20k | -- | 2.87 | -- | 3.38 | -1.54 | -1.54 | 9.70 | 11.43 | 0.5137 | 2.31 | 5.08 | 267,262.50 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 95.65m | 1.13m | 1.27bn | 325.00 | 1,025.82 | 2.75 | 82.11 | 13.25 | 0.0704 | 0.0704 | 5.93 | 26.29 | 0.1473 | 3.06 | 2.88 | 294,307.90 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| BB BIOTECH AG | 270.74m | 307.74m | 2.25bn | -- | 7.25 | 0.9023 | -- | 8.33 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| Dottikon ES Holding AG | 338.23m | 86.17m | 3.60bn | 694.00 | 41.20 | 4.21 | 33.55 | 10.64 | 6.24 | 6.24 | 24.49 | 61.10 | 0.3135 | 0.6339 | 5.39 | 498,861.30 | 7.99 | 7.48 | 9.58 | 8.48 | 67.58 | 78.94 | 25.48 | 22.35 | 1.65 | 101.25 | 0.1062 | -- | 26.80 | 15.09 | 47.94 | 27.70 | 30.78 | -- |
| Siegfried Holding AG | 1.27bn | 112.06m | 3.97bn | 3.93k | 33.49 | 4.46 | 20.47 | 3.12 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
| BACHEM HOLDING AG | 577.32m | 111.86m | 6.73bn | 2.01k | 59.86 | 5.10 | 42.86 | 11.66 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Sandoz Group AG | -100.00bn | -100.00bn | 13.75bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 09 May 2024 | 154.75k | 3.43% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 141.68k | 3.14% |
| BlackRock Fund Advisorsas of 12 Apr 2024 | 133.65k | 2.96% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2022 | 132.98k | 2.95% |
| Credit Suisse Asset Management (Schweiz) AGas of 19 Feb 2024 | 129.57k | 2.87% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 108.46k | 2.40% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 80.14k | 1.78% |
| Coeli Asset Management ABas of 17 May 2024 | 42.23k | 0.94% |
| AXA Investment Managers (Paris) SAas of 30 Apr 2024 | 35.09k | 0.78% |
| Templeton Investment Counsel LLCas of 31 Mar 2024 | 28.94k | 0.64% |
